Drug · CHEMBL672
FENOFIBRATE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. FENOFIBRATE. Drugs and targets, record CHEMBL672. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL672
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Antara, Antara (micronized), Fenofibrate (micronized), Fenogal, Fenoglide, Lipantil, Lipantil micro 200, Lipantil micro 267, Lipantil micro 67, Lipidil, Lipofen, Supralip 160, Tricor, Tricor (micronized), Triglide
- ChEMBL
- Open Targets' highest stage
- Approval, for 9 of its 57 diseases, from ATC, DailyMed, EMA Human Drugs and PMDA
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PPARA | Peroxisome proliferator-activated receptor alpha | Peroxisome proliferator-activated receptor alpha agonist | AGONIST | https://conductscience.org/library/genes/5465 |
Source ChEMBL
Diseases57
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 57Source Open Targets
See all 57 diseasesTrials175
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00000620 | Action to Control Cardiovascular Risk in Diabetes (ACCORD) | Phase 3 | 10,251 | 2014-09-15 | fenofibrate | Its name | ClinicalTrials.gov |
| NCT00542178 | Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study) | Phase 3 | 3,472 | 2013-11-26 | fenofibrate | Its name | ClinicalTrials.gov |
| NCT03439345 | Lowering Events in Non-proliferative Retinopathy in Scotland | Phase 4 | 1,151 | 2025-05-14 | fenofibrate | Its name | ClinicalTrials.gov |
| NCT00673309 | Assessment of Mechanisms of Improved Wound Healing | Phase 2/3 | 644 | 2019-12-16 | fenofibrate | Its name | ClinicalTrials.gov |
| NCT01674712 | A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease | Phase 3 | 575 | 2014-10-30 | fenofibrate | Its name | ClinicalTrials.gov |
| NCT01462877 | A Study to Evaluate Fenofibrate Combination With Statin in Chinese Patients With Dyslipidemic | Phase 4 | 506 | 2015-02-23 | fenofibrate | Its name | ClinicalTrials.gov |
| NCT02642159 | Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia) | Phase 4 | 413 | 2018-05-01 | fenofibrate | Its name | ClinicalTrials.gov |
| NCT00559962 | Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS | Phase 2 | 260 | 2013-02-22 | fenofibrate | Its name | ClinicalTrials.gov |
| NCT00246376 | Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia | 221 | 2016-03-21 | fenofibrate | Its name | ClinicalTrials.gov | |
| NCT00504829 | Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia | Phase 2 | 220 | 2020-02-05 | fenofibrate, lcp-atorfen | Its name | ClinicalTrials.gov |
1 to 10 of 175
See all 175 trialsComparisons in its trials50
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Glycemia Trial: Intensive Control vs Glycemia Trial: Standard Control: Death From Any Cause in the Glycemia Trial. | 391 of 5,128 | 327 of 5,123 | 10,251 | NCT00000620 | Trial comparisons |
Glycemia Trial: Intensive Control vs Glycemia Trial: Standard Control: First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial. | 503 of 5,128 | 543 of 5,123 | 10,251 | NCT00000620 | Trial comparisons |
| Glycemia Trial: Intensive Control vs Glycemia Trial: Standard Control: serious adverse events | 137 of 5,128 | 107 of 5,123 | 10,251 | NCT00000620 | Trial comparisons |
| Lipid Trial: Fenofibrate vs Lipid Trial: Placebo: First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial. | 641 of 2,765 | 667 of 2,753 | 5,518 | NCT00000620 | Trial comparisons |
| Lipid Trial: Fenofibrate vs Lipid Trial: Placebo: First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial. | 291 of 2,765 | 310 of 2,753 | 5,518 | NCT00000620 | Trial comparisons |
| BP Trial: Intensive Control vs BP Trial: Standard Control: First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial. | 208 of 2,363 | 237 of 2,371 | 4,734 | NCT00000620 | Trial comparisons |
| BP Trial: Intensive Control vs BP Trial: Standard Control: Stroke in the Blood Pressure Trial. | 36 of 2,363 | 62 of 2,371 | 4,734 | NCT00000620 | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants With Occurrence of Major Cardiovascular Events (Myocardial Infarction, Stroke, Coronary or Peripheral Revascularisation) | 45 of 576 | 43 of 575 | 1,151 | NCT03439345 | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants With the Individual Component of Composite Primary Outcome: Treatment for Diabetic Retinopathy or Maculopathy | 17 of 576 | 28 of 575 | 1,151 | NCT03439345 | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants With The Development of Macular Oedema | 22 of 576 | 43 of 575 | 1,151 | NCT03439345 | Trial comparisons |
1 to 10 of 50
See all 50 comparisons in its trialsPapers from its trials195
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL672
GET https://conductscience.org/api/drugs/v1/CHEMBL672/diseases?page=2